Larry Biegelsen: Good afternoon. Thanks for taking the question. So, on the Q4 call, you said you’d be talking more about international markets later this year. And today I heard spending is going towards O-US clearances. And Ron, you spoke more about Europe and Asia in your prepared remarks today than I heard on the Q4 call. So my question is, does this imply you’re closer to other major market launches? And what are you including in the guidance for O-US markets in 2024? And I had one follow-up.
Ron Kurtz: Yes. I don’t think anything has changed, Larry. We continue to focus primarily on the U.S. market, but we pursue our regulatory filings outside the U.S. in attractive markets, and we certainly will be updating as we make progress in those.
Shelley Thunen: And I think as far as revenue goes in 2023, obviously in Canada that has grown nicely for us and been a good market for us. I think in terms of the other markets, these regulatory cycles are getting pretty long. For instance, in Europe, we’ve seen it longer than we originally anticipated and continues to get pushed out. And if we have anything, you know, outside of Canada internationally, I would expect in 2024, would be pretty modest.
Larry Biegelsen: Got it. And one follow-up question for me, utilization, it looks like it was about 9.2 LALs per LDD per month in the first quarter, and it grew about 5% a year. It looks like it’s a little slower than what we’ve seen the last few quarters. Why is that? And how are you guys thinking about utilization for the rest of this year? Thank you.
Shelley Thunen: So I think the difference between my numbers and your numbers is that we calculate the number of LALs per LDD by taking as the number of LALs over the number of LDDs installed at the beginning of the quarter, right. So you don’t get a lot of normal LAL revenue out of new installs. But in fact, kind of, if I look back, we were at 10.2 in the fourth quarter, and we were at 10.1 in the first quarter, which I think is terrific overall. And kind of, if you go back to, let’s say in Q4 of 2022, we were about 8.9. So I think that we’ve gotten good sequential growth, although a little dip in the third quarter of 2023 for seasonality.
Larry Biegelsen: All right, thanks, Shelley.
Operator: Thank you. And one moment for our next question. Our next question comes from the line of Steve Lichtman with Oppenheimer & Co. Your line is open. Please go ahead.
Steve Lichtman: Thank you. Hi, Ron and Shelly, and congratulations. Wanted to ask, Ron, I think you mentioned targeting optometrists in terms of driving awareness. I think you talked to that ASCRS as well. Can you talk a little bit about what that looks like in this field in terms of how you approach that and some of the potential benefits in terms of referrals and things like that from targeting that group? Thanks.
Ron Kurtz: Yes. So optometry is obviously a very significant part of eye care, particularly in the U.S. and are integrally involved with cataract surgery both in terms of counseling of patients preoperatively as well as helping to manage patients through the course of their post op-periods. And that can be either independent or separate optometric practices that work in conjunction with ophthalmic offices, or it can be optometrists within ophthalmic practices. And we obviously for those practices that have our technology, many of them have optometrists, and we work very closely with them. Many of them have become very experienced and knowledgeable about our technology. They are often – just as academically minded as the ophthalmologists and like to present at their respective meetings.
And we see more of that, and we certainly want to support that. And then through our ophthalmic practices, we certainly want to support their educational events with optometrists in their community as well. And that’s something that’s important in driving awareness of the technology, which is very attractive, just fundamentally to optometrists generally because it fits with their overall ethos of quality of vision.
Steve Lichtman: Great. And then just as a quick follow-up. Are you adding to the salesforce on the LDD side this year? And if so, how much are you increasing that?
Shelley Thunen: Yes. I think that if we look at our planned headcount ads, they’re primarily in our clinical applications and LAL folks who work closely with the LDD. We may add a few on LDD, but certainly not at the rate that we add to those two other groups.
Steve Lichtman: Got it. Great. Thank you.
Ron Kurtz: Thank you, Steve.
Shelley Thunen: Thank you, Steve.
Operator: Thank you. And I would now like to hand the conference back to CEO, Ron Kurtz for closing remarks.
Ron Kurtz: Well, thank you all for your time and attention today. We appreciate your interest in RxSight and look forward to updating you on our progress in future quarters. Goodbye.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
